NASDAQ: RARE
Ultragenyx Pharmaceutical Inc.
Healthcare · Biotechnology
After hours: $25.70(-0.81%) · as of 7:34 PM ET
Market Cap
$2.55B
52w High
$39.89
52w Low
$18.29
P/E
-4.44
Volume
3.55M
Outstanding Shares
98.49M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 6.9% over the last year. Revenue grew 17.5% over the trailing twelve months. Operating margin moved from -82.78% to -73.77%. Free cash flow declined 14.55% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -73.77%. A decisive move in revenue — currently up 17.5% — would be the clearest signal to resolve the ambiguity.
Company profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
26
Buy
6
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 3, 2026
Q4 FY26 · EPS est -$1.00 · Revenue est $183.95M
View